FDA launch­es crim­i­nal probe in­to unau­tho­rized her­pes vac­cine R&D backed by Pe­ter Thiel

The Food and Drug Ad­min­is­tra­tion has launched a crim­i­nal in­ves­ti­ga­tion in­to re­search by a South­ern Illi­nois Uni­ver­si­ty pro­fes­sor who in­ject­ed peo­ple with his unau­tho­rized her­pes vac­cine, Kaiser Health News has learned.

SIU pro­fes­sor William Hal­ford, who died in June, in­ject­ed par­tic­i­pants with his ex­per­i­men­tal her­pes vac­cine in St. Kitts and Nevis in 2016 and in Illi­nois ho­tel rooms in 2013 with­out safe­ty over­sight that is rou­tine­ly per­formed by the FDA or an in­sti­tu­tion­al re­view board.

Ac­cord­ing to four peo­ple with knowl­edge about the in­quiry, the FDA’s Of­fice of Crim­i­nal In­ves­ti­ga­tions is look­ing in­to whether any­one from SIU or Hal­ford’s for­mer com­pa­ny, Ra­tio­nal Vac­cines, vi­o­lat­ed FDA reg­u­la­tions by help­ing Hal­ford con­duct unau­tho­rized re­search. The probe is al­so look­ing at any­one else out­side the com­pa­ny or uni­ver­si­ty who might have been com­plic­it, ac­cord­ing to the sources who asked not to be iden­ti­fied be­cause of the sen­si­tiv­i­ty of the mat­ter.

The FDA rarely pros­e­cutes re­search vi­o­la­tions, usu­al­ly choos­ing to ad­min­is­tra­tive­ly sanc­tion or ban re­searchers or com­pa­nies from fu­ture clin­i­cal tri­als, le­gal ex­perts said. Even so, the agency is em­pow­ered to pur­sue as a crime the unau­tho­rized de­vel­op­ment of vac­cines and drugs — and some­times goes af­ter such cas­es to send a mes­sage.

In this case, hu­man-sub­ject vi­o­la­tions would be deemed es­pe­cial­ly se­ri­ous giv­en Hal­ford was not a med­ical doc­tor and had in­ject­ed peo­ple with his ex­per­i­men­tal vac­cine with­out any rou­tine over­sight, ex­perts said.

“Since the re­search ap­pears to be an ef­fort to to­tal­ly evade FDA over­sight and is egre­gious, it makes sense the FDA would in­ves­ti­gate it as a crim­i­nal mat­ter,” said Pa­tri­cia Zettler, a for­mer FDA lawyer who was told of the crim­i­nal in­ves­ti­ga­tion by KHN. “There is a de­ter­rent ef­fect for oth­ers who might con­sid­er this a very brazen way to get out of hu­man sub­ject and FDA re­quire­ments.”

The FDA de­clined to com­ment. Ra­tio­nal Vac­cines did not re­spond to re­quests for com­ment. An SIU spokes­woman said, with­out elab­o­ra­tion, “The gov­ern­ment is in­ves­ti­gat­ing and we are co­op­er­at­ing.”

Any re­sult­ing crim­i­nal pros­e­cu­tion from the in­ves­ti­ga­tion could have po­lit­i­cal ram­i­fi­ca­tions.

Ra­tio­nal Vac­cines was co-found­ed with Hol­ly­wood film­mak­er Agustín Fer­nán­dez III and the com­pa­ny re­ceived mil­lions of dol­lars in pri­vate in­vest­ment from in­vestors af­ter the Caribbean tri­al, in­clud­ing from bil­lion­aire Pe­ter Thiel.

Thiel, who for months has re­fused to re­spond to ques­tions from KHN, con­tributed to Pres­i­dent Don­ald Trump’s cam­paign and is a high-pro­file crit­ic of the FDA. Thiel is part of a larg­er lib­er­tar­i­an move­ment to roll back FDA reg­u­la­tions to speed up med­ical in­no­va­tion.

The sources fa­mil­iar with the in­quiry said the FDA’s Of­fice of Crim­i­nal In­ves­ti­ga­tions, which has dozens of of­fices across the coun­try, be­gan to ag­gres­sive­ly pur­sue the case weeks ago.

The in­ves­ti­ga­tors have in­ter­viewed wit­ness­es across the coun­try, ask­ing them to iden­ti­fy Hal­ford’s as­so­ciates, and have de­scribed his ac­tions as pos­si­ble vi­o­la­tions of hu­man-sub­ject guide­lines and of FDA reg­u­la­tions, the sources told KHN.

The in­ves­ti­ga­tors al­so have ex­pressed in­ter­est in whether Hal­ford’s for­mer as­so­ciates at the uni­ver­si­ty or oth­er re­searchers and med­ical pro­fes­sion­als out­side the uni­ver­si­ty might have helped or known about his con­duct, the sources said. They al­so have raised ques­tions about the com­pa­ny’s knowl­edge of the vi­o­la­tions.

Ra­tio­nal Vac­cines helped over­see the Caribbean tri­al, but the 2013 ho­tel in­jec­tions took place be­fore the com­pa­ny was formed.

Un­der a Supreme Court rul­ing, a cor­po­rate of­fi­cial may be pros­e­cut­ed for a crim­i­nal mis­de­meanor of­fense un­der the Fed­er­al Food, Drug and Cos­met­ic Act even with­out proof that the of­fi­cial act­ed with in­tent or ac­tu­al knowl­edge of the of­fense.

Ini­tial­ly, uni­ver­si­ty of­fi­cials and Ra­tio­nal Vac­cines pub­licly de­fend­ed Hal­ford’s re­search. Ra­tio­nal Vac­cines has said it con­sid­ered the 2016 tri­al a suc­cess — though it is un­clear what da­ta it used to sup­port that claim.

Af­ter KHN’s in­ves­ti­ga­tion re­vealed that Hal­ford in­ject­ed peo­ple in the Unit­ed States, not just in the Caribbean, Ra­tio­nal Vac­cines took down its web­site, al­though it had vowed to con­tin­ue re­search.

SIU, a state uni­ver­si­ty with a med­ical school in Spring­field, IL, ini­tial­ly said it bore no re­spon­si­bil­i­ty for the ex­per­i­ments be­cause Hal­ford con­duct­ed the re­search in­de­pen­dent­ly and over­seas.

Af­ter Kaiser Health News raised ques­tions about Hal­ford’s prac­tices, the De­part­ment of Health and Hu­man Ser­vices asked the uni­ver­si­ty to de­ter­mine whether his ac­tiv­i­ties vi­o­lat­ed the in­sti­tu­tion’s pledge to HHS to fol­low hu­man-sub­ject safe­ty pro­to­cols for all re­search. SIU’s med­ical school re­ceives about $9 mil­lion a year in fed­er­al re­search dol­lars.

SIU has since ac­knowl­edged that Hal­ford’s con­duct vi­o­lat­ed uni­ver­si­ty rules and US laws. Uni­ver­si­ty of­fi­cials have de­nied know­ing about his mis­con­duct, an as­ser­tion that FDA in­ves­ti­ga­tors are still prob­ing, the sources said.

Hal­ford’s ac­tions al­ready raised un­usu­al le­gal ques­tions be­cause the FDA would not or­di­nar­i­ly have ju­ris­dic­tion over clin­i­cal tri­als when they oc­cur over­seas and the re­searchers have not sought FDA ap­proval.

It’s al­so un­clear where Hal­ford man­u­fac­tured the vac­cine.

If it was man­u­fac­tured in the Unit­ed States, the FDA like­ly has ju­ris­dic­tion, said Zettler, a law pro­fes­sor at Geor­gia State Uni­ver­si­ty.

The OCI of­ten goes af­ter such cas­es of con­t­a­m­i­nat­ed food, coun­ter­feit or off-la­bel phar­ma­ceu­ti­cals. The of­fice was cre­at­ed in the wake of a 1988 scan­dal in which phar­ma­ceu­ti­cal ex­ec­u­tives bribed FDA of­fi­cials in ex­change for speed­ing up gener­ic drug ap­provals.

While rare, the OCI oc­ca­sion­al­ly pur­sues re­search abus­es as a crime. A Glax­o­SmithK­line re­searcher, for in­stance, plead­ed guilty in 2010 to charges re­lat­ed to her fab­ri­ca­tion of da­ta in a study of chil­dren tak­ing the an­ti­de­pres­sant Pax­il. Glax­o­SmithK­line lat­er agreed to plead guilty and to pay $3 bil­lion to re­solve its crim­i­nal and civ­il li­a­bil­i­ty in the case.


By Marisa Tay­lor. Orig­i­nal­ly post­ed at Kaiser Health News, a na­tion­al health pol­i­cy news ser­vice that is part of the non­par­ti­san Hen­ry J Kaiser Fam­i­ly Foun­da­tion.

Bob Nelsen (Photo by Michael Kovac/Getty Images)

With stars aligned and cash in re­serve, Bob Nelsen's Re­silience plans a makeover at 2 new fa­cil­i­ty ad­di­tions to its drug man­u­fac­tur­ing up­start

Bob Nelsen’s new, state-of-the-art drug manufacturing initiative is taking shape.

Just 3 months after gathering $800 million of launch money, a dream team board and a plan to shake up a field where he found too many bottlenecks and inefficiencies for the era of Covid-19, Resilience has snapped up a pair of facilities now in line for a retooling.

The company has acquired a 310,000-square-foot plant in Boston from Sanofi along with a 136,000-square-foot plant in Ontario to add to a network which CEO Rahul Singhvi says is just getting started on building his company’s operations up. The Sanofi deal comes with a contract to continue manufacturing one of its drugs.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,300+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Mer­ck pulls Keytru­da in SCLC af­ter ac­cel­er­at­ed nod. Is the FDA get­ting tough on drug­mak­ers that don't hit their marks?

In what could be an early shot in the battle against drugmakers that whiff on confirmatory studies to support accelerated approvals, the FDA ordered Bristol Myers Squibb late last year to give up Opdivo’s approval in SCLC. Now, Merck is next on the firing line — are we seeing the FDA buckling down on post-marketing offenders?

Merck has withdrawn its marketing approval for PD-(L)1 inhibitor Keytruda in metastatic small cell lung cancer as part of what it describes as an “industry-wide evaluation” by the FDA of drugs that do not meet the post-marketing checkpoints on which their accelerated nods were based, the company said Monday.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,300+ biopharma pros reading Endpoints daily — and it's free.

Pascal Soriot, AstraZeneca CEO (AP Images)

Pas­cal So­ri­ot cash­es in As­traZeneca’s chips on Mod­er­na for $1.2B cash in­jec­tion

While still working to prove its own Covid-19 vaccine, AstraZeneca has reportedly capitalized on the success of another.

The company has sold off its 7.7% stake in Moderna and turned it into $1.2 billion in cash, according to the Times, beefing up the reserves just as Pascal Soriot is wrapping up his $39 billion acquisition of Alexion and its rare disease pipeline.

AstraZeneca’s stock sale follows a similar move by Merck in December. But like its pharma brethren, the British giant is keeping its R&D collaborations with Moderna.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,300+ biopharma pros reading Endpoints daily — and it's free.

Af­ter bail­ing on Covid-19 vac­cines, Mer­ck will team up with J&J to pro­duce its shot as part of un­usu­al Big Phar­ma pact

Merck took a big gamble when it opted to jump into the Covid-19 vaccine race late, and made an equally momentous decision to back out in late January. Now, looking to chip in on the effort, Merck reportedly agreed to team up with one of the companies that has already crossed the finish line.

President Joe Biden on Tuesday is expected to announce a partnership between drugmakers Merck and Johnson & Johnson to jointly produce J&J’s recombinant protein Covid-19 vaccine that received the FDA’s emergency use authorization Saturday, the Washington Post reported.

Ab­b­Vie tees up a biotech buy­out af­ter siz­ing up their Parkin­son's drug spun out of Ke­van Shokat's lab

AbbVie has teed up a small but intriguing biotech buyout after looking over the preclinical work it’s been doing in Parkinson’s disease.

The company is called Mitokinin, a Bay Area biotech spun out of the lab of UCSF’s Kevan Shokat, whose scientific explorations have formed the academic basis of a slew of startups in the biotech hub. One of Shokat’s PhD students in the lab, Nicholas Hertz, co-founded Mitokinin using their lab work on PINK1 suggesting that amping up its activity could play an important role in regulating the mitochondrial dysfunction contributing to Parkinson’s disease pathogenesis and progression.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,300+ biopharma pros reading Endpoints daily — and it's free.

Paul Sekhri

The next big biotech su­per­star? Paul Sekhri has some thoughts on that

It occasionally occurs to Paul Sekhri that if they pull this off, his company will be on the front page of the New York Times and a lead story in just about every major news outlet on the planet. He tries not to dwell on it, though.

“I just want to be laser-focused on getting to that point,” Sekhri says, before acknowledging, “Yes, it absolutely crossed my mind.”

Sekhri, a longtime biopharma executive with tenures at Sanofi and Novartis, is now entering year three as CEO of eGenesis, the biotech that George Church protégé Luhan Yang founded to genetically alter pigs so that they can be used for organ transplants. He led them through one megaround and has just closed another, raising $125 million from 17 different investors to push the first-ever (humanized) pig to human transplants into the clinic.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,300+ biopharma pros reading Endpoints daily — and it's free.

Fi­bro­Gen shares skid low­er as a sur­prise ad­comm rais­es risks on roxa OK

FibroGen will likely have to delay its US rollout for roxadustat once again.

In an unexpected move, the FDA is convening its Cardiovascular and Renal Drugs Advisory Committee to review the NDA in an advisory committee meeting. The date is yet to be confirmed.

Just a few weeks ago, SVB Leerink analyst Geoffrey Porges predicted that the roxa approval could come ahead of the PDUFA date on March 20 — effusive despite already being let down once by the FDA’s extension of its review back in December. AstraZeneca, which is partnered with FibroGen on the chronic kidney disease-related anemia drug, disclosed regulators had requested further clarifying analyses of clinical data.

In­tro­duc­ing End­pointsF­DA+, our new pre­mi­um week­ly reg­u­la­to­ry news re­port led by Zachary Bren­nan

CRLs. 483s. CBER, CDER and RWE. For biopharma professionals, these acronyms command attention because of the fundamental role FDA plays in drug development. Now Endpoints is doubling down on regulatory coverage, and launching a weekly report focusing on developments out of White Oak, with analysis and insight into what it all means.

Coverage will be led by our new senior editor, Zachary Brennan. He joins Endpoints from POLITICO, where he covered pharma. Prior to that he was the managing editor for Regulatory Focus, a news publication from the Regulatory Affairs Professionals Society.

UP­DAT­ED: Feds clear the road for J&J to start de­liv­er­ing mil­lions of dos­es of their Covid-19 vac­cine — but frets linger about run­ner-up sta­tus

All the pieces needed to trigger a third wave of Covid-19 vaccine supply to start washing over the US fell neatly into place over the weekend.

After providing for a brief mime of regulatory judiciousness, the FDA stamped their emergency approval on J&J’s Covid-19 vaccine Saturday, adding to the Biden administration’s plan aimed at ending the pandemic in the near term — at least in the US. The CDC came through on Sunday with its stamp of approval and J&J is reportedly expected to start delivering vaccine sometime in the next few days.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,300+ biopharma pros reading Endpoints daily — and it's free.